Immix Biopharma | Investor Presentation Deck | 62 slides · page 45 of 62
The slide highlights that NXC-201 has no exclusion for prior BCMA therapy, unlike the other listed treatments.
Pitch deck · comparison_table · compare_peers · sparse density
Slide locked Sign in to view
Slide schematic 3/3
source-note 1/1 table 1/1 title 1/1
Components 3
source-note data headline
Tools 0
∅
No tools
No canon tool match is anchored to this slide.
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 1